14.56
price down icon0.61%   -0.09
after-market After Hours: 14.75 0.19 +1.30%
loading
Myriad Genetics Inc stock is traded at $14.56, with a volume of 1.14M. It is down -0.61% in the last 24 hours and up +6.43% over the past month. Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
See More
Previous Close:
$14.65
Open:
$14.83
24h Volume:
1.14M
Relative Volume:
1.14
Market Cap:
$1.33B
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-11.20
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+17.32%
1M Performance:
+6.43%
6M Performance:
-47.27%
1Y Performance:
-37.80%
1-Day Range:
Value
$14.44
$14.98
1-Week Range:
Value
$12.13
$14.98
52-Week Range:
Value
$12.04
$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Name
Name
Myriad Genetics Inc
Name
Phone
801-584-3600
Name
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Name
Employee
2,700
Name
Twitter
@myriadgenetics
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MYGN's Discussions on Twitter

Compare MYGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
MYGN
Myriad Genetics Inc
14.56 1.33B 823.60M -116.00M -107.30M -1.30
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
531.85 203.43B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
206.30 148.35B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
A
Agilent Technologies Inc
134.67 38.42B 6.51B 1.29B 1.37B 4.42
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
444.53 36.40B 3.90B 887.87M 808.08M 10.67
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
193.44 34.06B 15.41B 1.37B 2.11B 7.50

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-12-25 Initiated Craig Hallum Buy
Dec-10-24 Initiated UBS Neutral
Dec-09-24 Downgrade Leerink Partners Outperform → Market Perform
Sep-19-24 Initiated Morgan Stanley Equal-Weight
Aug-28-24 Initiated Wells Fargo Overweight
Jun-27-24 Initiated Scotiabank Sector Outperform
Jun-03-24 Resumed Jefferies Underperform
May-08-24 Upgrade Leerink Partners Market Perform → Outperform
Dec-21-23 Resumed Piper Sandler Neutral
Dec-19-23 Initiated Wells Fargo Equal Weight
Dec-14-23 Initiated Guggenheim Buy
Dec-13-23 Initiated Wolfe Research Outperform
Jul-05-23 Resumed JP Morgan Underweight
May-23-23 Upgrade Goldman Sell → Buy
Jan-18-23 Upgrade Raymond James Mkt Perform → Outperform
Oct-06-22 Initiated Stephens Equal-Weight
Oct-15-21 Resumed Cowen Market Perform
Jun-15-21 Initiated Raymond James Mkt Perform
Jun-03-21 Initiated Goldman Sell
Sep-26-19 Downgrade BofA/Merrill Neutral → Underperform
Aug-14-19 Downgrade Piper Jaffray Overweight → Neutral
Aug-02-19 Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19 Upgrade Barclays Underweight → Equal Weight
Jul-29-19 Downgrade Needham Strong Buy → Hold
Jul-09-19 Downgrade Cowen Outperform → Market Perform
Mar-12-19 Reiterated Needham Strong Buy
Jan-03-19 Initiated Needham Strong Buy
Nov-30-18 Upgrade Goldman Sell → Neutral
Oct-10-18 Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18 Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18 Initiated Goldman Sell
Jan-22-18 Reiterated Barclays Equal Weight
Jan-05-18 Initiated BTIG Research Buy
Oct-02-17 Resumed Leerink Partners Mkt Perform
Aug-09-17 Reiterated Barclays Equal Weight
Feb-08-17 Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17 Initiated Deutsche Bank Sell
Oct-10-16 Downgrade Ladenburg Thalmann Neutral → Sell
View All

Myriad Genetics Inc Stock (MYGN) Latest News

pulisher
03:34 AM

Myriad Genetics (NASDAQ:MYGN) Trading Up 8.3%Still a Buy? - MarketBeat

03:34 AM
pulisher
01:23 AM

Insiders Sold US$6.5m Of Myriad Genetics Stock Possibly Sending Warning Sign - Simply Wall St

01:23 AM
pulisher
04:11 AM

Genomic Biomarker Market Projected To Witness Substantial Growth, 2025-2032: Myriad Genetics, Inc., Eurofins - EIN News

04:11 AM
pulisher
Feb 13, 2025

Craig Hallum Begins Coverage on Myriad Genetics (NASDAQ:MYGN) - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

PARP Inhibitor Biomarkers Market Top Players- Myriad Genetics, - openPR

Feb 13, 2025
pulisher
Feb 12, 2025

Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

Craig-Hallum initiates Myriad Genetics stock with a Buy rating By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 11, 2025

MYGN Stock Might Rise on Collaboration With CancerCARE - MSN

Feb 11, 2025
pulisher
Feb 10, 2025

Jennison Associates LLC Raises Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Feb 10, 2025
pulisher
Feb 07, 2025

Myriad Genetics secures patents for cancer MRD tests - MSN

Feb 07, 2025
pulisher
Feb 06, 2025

Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing - Nasdaq

Feb 06, 2025
pulisher
Feb 06, 2025

Myriad Genetics and CancerCARE for Life Announce Agreement - GlobeNewswire

Feb 06, 2025
pulisher
Feb 06, 2025

Major Healthcare Partnership: Myriad's Advanced Cancer Risk Test Now Available to Million-Plus Patients - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewswire

Feb 06, 2025
pulisher
Feb 06, 2025

Predictive Genetic Counselling Market Size, Trends, - openPR

Feb 06, 2025
pulisher
Feb 06, 2025

Myriad Genetics and Lumea Collaborate to Enhance Access to - GlobeNewswire

Feb 06, 2025
pulisher
Feb 05, 2025

Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay -February 05, 2025 at 05:41 pm EST - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Myriad Genetics secures patents for cancer MRD tests By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Myriad Genetics Partners With Lumea To Integrate Prolaris And MyRisk Tests Into BxLink Platform - Nasdaq

Feb 05, 2025
pulisher
Feb 05, 2025

Myriad Genetics and Lumea Inc. Announce Integration of Advanced Molecular Diagnostic Tests into Digital Pathology Platform BxLink - Nasdaq

Feb 05, 2025
pulisher
Feb 05, 2025

Lumea and Myriad Genetics Collaborate to Enhance Access to Biomarker and Hereditary Cancer Tests in BxLink - EIN News

Feb 05, 2025
pulisher
Feb 05, 2025

Pancreatic Cancer Market Size USD 5.7 Billion, Opportunities, - openPR

Feb 05, 2025
pulisher
Feb 05, 2025

Blue Trust Inc. Boosts Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

Feb 05, 2025
pulisher
Feb 04, 2025

Piper Sandler Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $14.00 - MarketBeat

Feb 04, 2025
pulisher
Feb 02, 2025

Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Feb 02, 2025
pulisher
Feb 01, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC - Defense World

Feb 01, 2025
pulisher
Feb 01, 2025

Piper Sandler Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price - Defense World

Feb 01, 2025
pulisher
Feb 01, 2025

Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $18.00 by Analysts at The Goldman Sachs Group - MarketBeat

Feb 01, 2025
pulisher
Jan 29, 2025

Myriad Genetics Unveils Award-Winning Research on Early Prenatal Screening Technology at SMFM Conference - Nasdaq

Jan 29, 2025
pulisher
Jan 29, 2025

Myriad Genetics Unveils Groundbreaking Eight Weeks’ - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR

Jan 29, 2025
pulisher
Jan 28, 2025

Cancer Diagnostics Market Top Companies StudyDanaher - openPR

Jan 28, 2025
pulisher
Jan 27, 2025

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

(MYGN) Trading Advice - Stock Traders Daily

Jan 27, 2025
pulisher
Jan 26, 2025

Myria and Beacher’s Madhouse to Bring an Unforgettable Spectacle to New Orleans During Big Game Weekend - GlobeNewswire Inc.

Jan 26, 2025
pulisher
Jan 26, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 24, 2025

Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? - Yahoo Finance

Jan 24, 2025
pulisher
Jan 24, 2025

MYGN Stock Gains Following the Launch of Know More Sooner - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Myriad Genetics (NASDAQ:MYGN) Reaches New 12-Month LowHere's Why - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

FY2024 EPS Forecast for Myriad Genetics Increased by Analyst - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Myriad Genetics stock hits 52-week low at $12.16 amid market challenges - Investing.com

Jan 23, 2025
pulisher
Jan 23, 2025

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource - Yahoo Finance

Jan 23, 2025
pulisher
Jan 23, 2025

FY2024 EPS Estimates for Myriad Genetics Raised by Analyst - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Genomic Biomarker Market Growth in Future Scope 2025-2032 | - openPR

Jan 23, 2025

Myriad Genetics Inc Stock (MYGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
diagnostics_research DGX
$168.77
price up icon 0.03%
diagnostics_research LH
$246.49
price up icon 0.66%
$173.39
price up icon 1.56%
diagnostics_research WAT
$369.73
price down icon 2.47%
diagnostics_research MTD
$1,271.91
price down icon 1.95%
diagnostics_research IQV
$193.44
price down icon 1.33%
Cap:     |  Volume (24h):